Cancer drug maker Biostar shines on Hong Kong market debut
Unusually for a newly listed biotech, the company has already launched a commercial product – a flagship oncology drug that was developed using synthetic biotechnology Key Takeaways: The active agent…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
